Cancer Centers of the Carolinas- Easley
Easley, South Carolina 29640
0 studies enrolling now · 13 studies all time
What they study most
Brain and Central Nervous System Tumors, Breast Cancer, Chemotherapeutic Agent Toxicity, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Fatigue, Leukemia, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Neuropathy
Studies at this site
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Running, not enrolling
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer — Completed
- Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy — Completed
- informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia — Status unconfirmed
- S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer — Completed
- Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme — Completed
- S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases — Completed
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo — Completed
- S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo — Completed
- Collection of Patient-Reported Symptoms and Performance Status Via the Internet — Completed
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab — Completed
- S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer — Completed